SRPT: Sarepta Therapeutics, Inc.
About
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
Current Value
$110.461 Year Return
Current Value
$110.461 Year Return
Key Details
Market Cap
$10.18B
P/E Ratio
88.57
1Y Stock Return
26.81%
1Y Revenue Growth
48.45%
Dividend Yield
0.00%
Price to Book
8.3
Strategies that include SRPT
Stock's related to SRPT
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DORM | 39.16% | $4.14B | +89.68% | 0.00% |
| JNPR | 37.85% | $11.61B | +30.55% | 2.49% |
| CTLT | 37.53% | $10.69B | +47.79% | 0.00% |
| PSMT | 36.28% | $2.70B | +32.81% | 1.34% |
| PETS | 34.53% | $93.60M | -41.21% | 0.00% |
| ASAN | 33.96% | $3.14B | -33.65% | 0.00% |
| PRTA | 32.19% | $756.01M | -56.52% | 0.00% |
| RCKT | 31.95% | $1.20B | -39.83% | 0.00% |
| WRAP | 28.82% | $62.86M | -49.45% | 0.00% |
| ACET | 28.49% | $84.87M | -10.43% | 0.00% |
| SMG | 28.00% | $4.24B | +35.01% | 3.52% |
| RARE | 27.09% | $4.17B | +16.19% | 0.00% |
| PBH | 27.02% | $4.07B | +41.93% | 0.00% |
| FATE | 26.05% | $248.29M | -11.02% | 0.00% |
| LILA | 26.04% | $1.37B | +2.95% | 0.00% |
| SW | 26.02% | $13.78B | +15.02% | 1.14% |
| VCEL | 25.63% | $2.76B | +55.60% | 0.00% |
| LILAK | 25.63% | $1.36B | +1.47% | 0.00% |
| IRWD | 25.53% | $609.71M | -59.34% | 0.00% |
| CAT | 25.49% | $184.59B | +53.29% | 1.41% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ROKU | 0.01% | $10.69B | -21.36% | 0.00% |
| AOSL | 0.01% | $933.92M | +47.50% | 0.00% |
| VNET | 0.02% | $954.90M | +33.82% | 0.00% |
| CRVO | 0.03% | $83.20M | +2.86% | 0.00% |
| GPK | -0.03% | $8.48B | +25.34% | 1.41% |
| OXSQ | 0.05% | - | - | 15.53% |
| KB | -0.05% | $24.84B | +59.60% | 4.17% |
| GIL | 0.06% | $7.55B | +37.20% | 1.63% |
| MVO | 0.06% | $106.15M | -22.78% | 16.78% |
| MYGN | -0.06% | $1.37B | -14.19% | 0.00% |
| ESNT | 0.06% | $5.93B | +16.81% | 1.96% |
| GIB.A | 0.06% | $24.72B | +8.31% | 0.00% |
| MKL | 0.07% | $21.48B | +16.38% | 0.00% |
| UFI | 0.07% | $102.66M | -11.22% | 0.00% |
| BCAN | -0.08% | $72.87M | -99.75% | 0.00% |
| PRKS | 0.08% | $3.08B | +14.79% | 0.00% |
| MTD | -0.08% | $24.49B | +6.92% | 0.00% |
| ASPN | 0.08% | $1.16B | +33.90% | 0.00% |
| GHG | 0.09% | $180.98M | -36.68% | 0.00% |
| VRCA | 0.10% | $40.58M | -75.88% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| GVA | -27.74% | $4.26B | +114.90% | 0.53% |
| SSTK | -23.23% | $1.03B | -34.23% | 3.95% |
| COCO | -22.83% | $2.01B | +24.49% | 0.00% |
| PINS | -21.09% | $20.07B | -5.95% | 0.00% |
| TWO | -20.83% | $1.21B | -15.84% | 15.54% |
| EVER | -18.68% | $664.25M | +124.76% | 0.00% |
| RGEN | -17.32% | $7.20B | -18.16% | 0.00% |
| NEXA | -16.61% | $1.02B | +30.44% | 0.00% |
| INSG | -16.21% | $157.28M | +540.25% | 0.00% |
| ANET | -15.12% | $118.95B | +75.41% | 0.00% |
| PRPO | -14.85% | $9.10M | -13.65% | 0.00% |
| ACGL | -14.41% | $36.00B | +16.84% | 0.00% |
| LDOS | -13.98% | $21.12B | +49.80% | 0.96% |
| UNM | -13.73% | $13.16B | +69.20% | 2.16% |
| MFIN | -13.71% | - | - | 4.31% |
| HPE | -13.44% | $27.96B | +37.84% | 2.42% |
| OTTR | -12.71% | $3.35B | +6.14% | 2.35% |
| RNR | -12.46% | $13.74B | +23.09% | 0.58% |
| QNTM | -12.25% | $9.19M | -94.36% | 0.00% |
| NERV | -12.02% | $14.69M | -58.00% | 0.00% |
ETF's related to SRPT
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| PINK | 54.68% | $161.15M | 0.5% |
| XBI | 36.38% | $6.58B | 0.35% |
| IBB | 31.85% | $6.66B | 0.45% |
| GNOM | 31.64% | $70.59M | 0.5% |
| PBE | 30.94% | $258.53M | 0.58% |
| BBH | 30.53% | $397.87M | 0.35% |
| PTH | 29.01% | $143.31M | 0.6% |
| FXH | 27.50% | $1.15B | 0.62% |
| XPH | 26.95% | $157.87M | 0.35% |
| FBT | 26.77% | $1.11B | 0.56% |
| VHT | 25.96% | $17.06B | 0.1% |
| FHLC | 25.85% | $2.73B | 0.084% |
| YYY | 25.47% | $538.03M | 4.6% |
| IHE | 24.82% | $596.23M | 0.39% |
| RSPA | 24.46% | $273.87M | 0% |
| IYH | 24.13% | $3.19B | 0.39% |
| RSPH | 23.83% | $885.96M | 0.4% |
| ARKG | 22.64% | $1.13B | 0.75% |
| QQA | 22.50% | $135.01M | 0% |
| XHE | 22.36% | $213.41M | 0.35% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| SHYD | 0.09% | $311.50M | 0.35% |
| MINT | 0.09% | $11.62B | 0.35% |
| HEDJ | 0.11% | $1.49B | 0.58% |
| XOP | 0.17% | $2.58B | 0.35% |
| AGZD | 0.17% | $142.76M | 0.23% |
| IAK | -0.22% | $760.79M | 0.39% |
| EWI | 0.23% | $370.56M | 0.5% |
| RSPG | -0.25% | $544.63M | 0.4% |
| BSJO | 0.27% | $467.93M | 0.43% |
| CRPT | -0.33% | $94.50M | 0.85% |
| SEIX | -0.33% | $268.81M | 0.62% |
| HEZU | -0.35% | $334.98M | 0.53% |
| EWJV | -0.35% | $258.12M | 0.15% |
| FENY | -0.41% | $1.64B | 0.084% |
| IYE | -0.41% | $1.35B | 0.39% |
| URNM | 0.43% | $1.61B | 0.75% |
| PXE | 0.43% | $117.58M | 0.63% |
| FLJP | 0.50% | $1.94B | 0.09% |
| VDE | -0.61% | $8.33B | 0.1% |
| FCG | 0.73% | $395.85M | 0.6% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -12.10% | $388.04M | 1.43% |
| VIXY | -11.53% | $195.31M | 0.85% |
| DBA | -10.23% | $755.88M | 0.93% |
| CPER | -9.92% | $159.52M | 0.97% |
| UUP | -9.59% | $309.25M | 0.77% |
| GCC | -9.53% | $133.23M | 0.55% |
| USCI | -9.48% | $185.47M | 1.07% |
| DBB | -9.16% | $126.37M | 0.77% |
| DBMF | -8.79% | $1.02B | 0.85% |
| FTGC | -8.71% | $2.17B | 1.02% |
| EQLS | -8.61% | $76.08M | 1% |
| TPMN | -8.55% | $40.60M | 0.65% |
| UNG | -8.35% | $908.80M | 1.06% |
| IBHD | -8.30% | $327.80M | 0.35% |
| BCD | -8.21% | $245.02M | 0.3% |
| CMDY | -7.46% | $279.14M | 0.28% |
| EPHE | -7.31% | $99.70M | 0.59% |
| KCCA | -7.30% | $220.51M | 0.87% |
| BCI | -7.29% | $1.20B | 0.26% |
| CTA | -7.14% | $350.27M | 0.78% |
News
Yahoo
We recently published a list of 12 High Growth Large Cap Stocks to Buy Now. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against other high growth large cap stocks. BlackRock highlighted that its portfolio managers are broadly optimistic about US equities. Its portfolio managers opine that […]
Yahoo
The latest earnings release from Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) disappointed investors. Our analysis found...
Yahoo
JPMorgan sees a long-term buying opportunity after Sarepta (SRPT) shares were under pressure last week post earnings. Near-term, if one believes that Sarepta is being overly conservative on Q4 Elevidys product guidance, current share levels offer a compelling buying opportunity, the analyst tells investors in a research note. And longer term, there is a “clear valuation disconnect,” with current levels pricing in essentially a 4-7 year-old Elevidys label scenario, which does not make sense given
SeekingAlpha
Investors consider Dyne Therapeutics' treatments for muscle diseases and strong cash position as a speculative Buy opportunity. Learn more on DYN stock here.
SeekingAlpha
Sarepta Therapeutics is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025. Learn more about SRPT stock here.
Yahoo
Baird lowered the firm’s price target on Sarepta (SRPT) to $193 from $200 and keeps an Outperform rating on the shares. The firm said Elevidys sales showed better-than-expected growth in 3Q with upbeat management commentary on the launch. Baird thinks all signals continue to point to a multi-billion-dollar product that can get complemented by several additional gene therapy launches over the next five years. Published first on TheFly – the ultimate source for real-time, market-moving breaking fi
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.